Oxypaeoniflorin improves myocardial ischemia/reperfusion injury by activating the Sirt1/Foxo1 signaling pathway

Kai Wang1 and Wei Hu2✉

1Department of TCM Pharmacy, Ningbo Medical Center Li Hui Hospital; 2Department of TCM Pharmacy, Huamei Hospital, Haishu District, Ningbo, Zhejiang Province, China Academy of Sciences

Myocardial ischemia/reperfusion (MI/R) injury is a leading cause of damage to cardiac tissues and is associated with high mortality and disability rates worldwide. Oxypaeoniflorin (OPA) has been found to be the main constituent of Paeonia veitchii Lynch. This study was conducted to explore the effect of OPA on MI/R injury and its potential mechanism. An in vivo MI/R injury model was established by transient coronary ligation in BALB/c mice, and an in vitro hypoxia/reoxygenation (H/R) injury model was established with rat cardiomyocyte H9c2 cells. Ecologicographic assessments demonstrated that OPA significantly reduced disruption of cardiac function and improved the indicators of ejection fraction (EF) and fractional shortening (FS). The enzyme-linked immunosorbent assay (ELISA) results suggested that OPA significantly reduced the release of myocardial infarction-related factors, such as the creatine kinase (CK-MB), cardiac troponin I (cTnI) and cardiac troponin T (cTnT). Additionally, hematoxylin-eosin (H&E) staining demonstrated that OPA markedly inhibited the myocardial apoptosis and necrosis caused by MI/R. Consistently, the results obtained from the cell counting kit-8 (CCK-8) and flow cytometry assays revealed that OPA obviously reversed the H/R-induced decrease in cell activity and increase in apoptosis of H9c2 cells. Furthermore, western blot assays indicated that OPA inhibited apoptosis by activating the Sirt1 (silent information regulator factor 2 related enzyme 1)/Foxo1 (forkhead transcription factor FKHR) signaling pathway in myocardial tissues and H9c2 cells. Collectively, these novel findings are the first to provide strong evidence that OPA attenuates MI/R injury by activating the Sirt1/Foxo1 signaling pathway, and the regulatory role of these signaling mediators in the myocardial ischemia/reperfusion injury could be a reasonable method of ameliorating the MI/R injury (Wang et al., 2016). Oxypaeoniflorin (OPA), also known as (1α,β-hexopyranosyl)-5-hydroxy-2-methyltetrahydro-1H-2,5-methano-3,4-dioxacyclobuta[cd]pentalen-5b(3αH)-yl)methyl 4-hydroxybenzoate, has a molecular formula of C29H26O15 and a molecular weight of 496.46 (Feng et al., 2010). OPA is a monoterpene glycoside compound very similar to paeoniflorin and oxypaeoniflorin. Among these components, paeoniflorin has been reported to alleviate myocardial injury by inhibiting inflammation and apoptosis (Nizamutdinova et al., 2008; Qian et al., 2015; Chen et al., 2015; Li et al., 2012; Han et al., 2016b). Oxypaeoniflorin (OPA), also known as (1α,β-hexopyranosyl)-5-hydroxy-2-methyltetrahydro-1H-2,5-methano-3,4-dioxacyclobuta[cd]pentalen-5b(3αH)-yl)methyl 4-hydroxybenzoate, has a molecular formula of C29H26O15 and a molecular weight of 496.46 (Feng et al., 2010). Oxypaeoniflorin improves myocardial ischemia/reperfusion injury by activating the Sirt1/Foxo1 signaling pathway.

Key words: Oxypaeoniflorin, myocardial ischemia/reperfusion, apoptosis, Sirt1/Foxo1

Received: 18 March, 2020; revised: 26 April, 2020; accepted: 20 May, 2020; available on-line: 18 June, 2020

INTRODUCTION

Ischemic heart disease, also known as coronary atherosclerotic heart disease (referred to as coronary heart disease), has become the leading cause of death worldwide (Finegold et al., 2013). According to the World Health Organization, coronary heart disease caused a total of 7.4 million deaths worldwide in 2012, and its incidence has increased annually in China (Zhu et al., 2016). Mounting evidence has demonstrated that the occlusion of blood vessels by coronary arteriosclerotic plaques due to myocardial ischemia can lead to myocardial tissue damage; after the vascular occlusion is removed, the process of regaining blood supply to the myocardial tissue causes further myocardial tissue damage, which is widely known as myocardial ischemia/reperfusion (MI/R) injury (Buja, 2013). MI/R injury can lead to many adverse complications, including cardiomyocyte necrosis and apoptosis, ultimately destroying the cardiac contractile function (Salas et al., 2010; Wang et al., 2019). Naturally, protecting cardiomyocytes from apoptosis and necrosis could be a reasonable method of ameliorating the MI/R injury (Wang et al., 2015; Zhu et al., 2015; Xu et al., 2019; Wang et al., 2016). Therefore, for the prevention and treatment of ischemic heart disease, it is of great significance to explore the mechanisms that regulate MI/R injury and those that protect against MI/R injury.
in the sham operation group were not ligated. The mice were randomly assigned to the following groups (6 mice for each group): (1) Sham group; (2) MI/R group; (3) MI/R + OPA (10 mg/kg) group; (4) MI/R + OPA (20 mg/kg) group, and (5) MI/R + OPA (40 mg/kg) group. OPA was administered intragastrically at the concentrations described above (diluted in sterile saline containing less than 1% dimethyl sulfoxide (DMSO)) every day for 30 days before the surgery. Finally, blood samples from the sacrificed mice were collected for biochemical analysis, and the hearts of the sacrificed rats were collected for pathological and biochemical examination.

**In vitro H/R cell model and treatment.** H9c2 cells were purchased from American Type Culture Collection (ATCC, Rockville, MD) and cultured in Dulbecco’s modified Eagle’s medium (Sigma-Aldrich, USA) with 1% penicillin/streptomycin and 10% fetal bovine serum (Sigma-Aldrich, USA). To establish the H/R injury model, the procedure was performed as previously described (Li et al., 2017). Briefly, H9c2 cells were cultured in an ischemic buffer. The pH of the buffer was 6.5, and the cells were incubated for 2 hours in a humidified cell incubator containing 21% oxygen and 5% CO2 at 37°C. Reperfusion was initiated by culturing the cells in normal medium for 4 hours under the above incubation conditions. Then, the cells were treated with OPA at different concentrations, and the experimental groups were as follows: (1) Control group; (2) H/R group; (3) H/R group + 0.1 μM OPA; (4) H/R group + 1 μM OPA; and (5) H/R group + 10 μM OPA. The cells were cultured for 8 hours in serum-free medium under the conditions described above before establishing the ischemia-reperfusion injury model.

**Echocardiography.** Two-dimensional echocardiography was performed using the VisualSonics Vevo 770 machine (VisualSonics, Toronto, ON, Canada) as previously described (Zhang et al., 2018). In brief, the mice were anesthetized by inhalation of 1.5% isoflurane 72 hours after MI/R surgery, and motion (M)-mode echocardiographic images were used to determine the left ventricular end systolic diameter (LVEDD) and left ventricular end diastolic diameter (LVESD). The ejection fraction (EF) and fractional shortening (FS) were calculated with the following equations:

\[
EF \% = \frac{LVEDD_0 - LVESD}{LVEDD_0} \times 100
\]

\[
FS \% = \frac{(LVEDD - LVESD)}{LVEDD} \times 100
\]

**Detection of the myocardial enzyme levels in the serum.** The mice were sacrificed after the peripheral blood was collected, and serum was separated to evaluate indicators of the heart muscle damage, including creatine kinase (CK-MB), cardiac troponin I (cTnI) and cardiac troponin T (cTnT), using an enzyme-linked immunosorbent assay kit (Thermo Fisher Scientific, USA).

**Hematoxylin-eosin (H&E) staining.** Two hours after MI/R surgery, the chests of mice were opened again. The hearts were separated from the aortic roots and washed with prechilled phosphate-buffered saline at 4°C, followed by fixation in 4% paraformaldehyde for 24 hours. Then, the hearts were embedded and cut into 4-μm sections by a paraffin slicing machine (Leica Microsystems, Germany). For H&E staining, the sections were deparaffinized in xylene, hydrated in serially diluted ethanol, and stained with hematoxylin and eosin staining kit for 10 min. Representative photomicrographs were captured by a light microscope (Olympus Corp., Tokyo, Japan).
**RESULTS**

**Effects of OPA on the cardiac functions in MI/R mice observed by echocardiographic assessment**

To investigate the effect of OPA on the cardiac function of MI/R mice, the left ventricular end systolic diameter (LVESD) and left ventricular end diastolic diameter (LVEDD) were measured by echocardiography to calculate the ejection fraction (EF) and fractional shortening (FS), which are indexes of LV systolic function. The results shown in Fig. 2A–C confirm that the mouse model of MI/R was successfully established, as shown by the following evidence. Compared to the mice in the Sham group, the mice in the MI/R group showed a decreased cardiac function, and the EF and FS of the MI/R group were decreased by approximately 40.48% and 29.98%, respectively (Fig. 2A–C). In addition, OPA (10, 20 and 40 mg/kg) observably reversed the abnormal EF and FS values in the mice subjected to MI/R injury in a dose-dependent manner (Fig. 2A–C). Specifically, compared with those in the MI/R group, the EF and FS in the MI/R+OPA (10 mg/kg) group increased by approximately 8.72% and 4.72%, the EF and FS in the MI/R+OPA (20 mg/kg) group increased by approximately 15.16% and 8.10%, and the EF and FS in the MI/R+OPA (40 mg/kg) group increased by approximately 22.55% and 13.21%, respectively. These data demonstrated that the MI/R injury model was suc-
cessfully established and that OPA could significantly improve cardiac function in the MI/R mice.

Effects of OPA on the myocardial enzyme markers in MI/R mice

To further explore the protective effects of OPA against MI/R injury, the levels of the myocardial enzyme CK-MB and the structural proteins cTnI and cTnT were evaluated in the serum of mice in different groups (Fig. 3A–C). Significantly increased levels of CK-MB, cTnI and cTnT were observed in the MI/R group compared to those in the Sham group. Compared with those in the Sham group, the levels of CK-MB, cTnI and cTnT in the MI/R group were significantly increased by 243.48 IU/L, 1.29 ng/mL and 1.34 ng/mL, respectively. OPA treatment dramatically reduced the MI/R-induced increase in the levels of CK-MB, cTnI and cTnT in a dose-dependent manner. Specifically, compared with those in the MI/R group, the levels of CK-MB, cTnI and cTnT in the MI/R+OPA (10 mg/kg) group decreased by approximately 91.25 IU/L, 0.24 ng/mL and 0.44 ng/mL, the levels of CK-MB, cTnI and cTnT in the MI/R+OPA (20 mg/kg) group decreased by approximately 141.66 IU/L, 0.73 ng/mL and 0.63 ng/mL, and the levels of CK-MB, cTnI and cTnT in the MI/R+OPA (20 mg/kg) group decreased by approximately 191.47 IU/L, 1.04 ng/mL and 0.98 ng/mL, respectively. These results suggested that OPA could ameliorate cardiac damage in the MI/R mice.

Effects of OPA on the histochemical alterations in MI/R mice

In the Sham group, the cardiomyocytes were well arranged, the myocardial fiber structure was normal, and no degeneration or myocardial necrosis was observed (Fig. 4). However, in contrast to the Sham group, the

Figure 3. Effects of OPA on the myocardial enzyme markers in MI/R mice. (A) Serum creatine kinase-MB (CK-MB) levels. (B) Serum cardiac troponin I (cTnI) levels. (C) Serum cardiac troponin T (cTnT) levels. *P<0.05, **P<0.01 compared with the Sham group; #P<0.05, ##P<0.01 compared with the MI/R group.

Figure 4. Effects of OPA on the histochemical alterations in MI/R mice. Histopathological changes in mouse cardiac tissues observed by H&E staining (200×, bar=100 μm).

Figure 5. OPA activates the Sirt1/Foxo1 signaling pathway and inhibits the apoptosis of cardiomyocytes in MI/R mice. (A) Representative images of the western blot results. (B) Quantitative densitometric analysis of the proteins. *P<0.05, **P<0.01 compared with the Sham group; #P<0.05, ##P<0.01 compared with the MI/R group.
MI/R group presented with ruptured myocardial fibers, karyopyknosis and fragmentation, and a large area of cardiac necrosis (Fig. 4). However, treatment with OPA significantly mitigated the MI/R-induced pathological alterations in a dose-dependent manner (Fig. 4). These data showed that OPA could protect cardiomyocytes from MI/R-induced necrosis.

OPA activates the Sirt1/Foxo1 signaling pathway and inhibits the apoptosis of cardiomyocytes in MI/R mice

Considering that the above results have clearly demonstrated that OPA can protect against the MI/R injury, we explored a potential mechanism that regulates this effect. We focused on the Sirt1/Foxo1-mediated apoptosis signaling pathway, which is related to the MI/R injury. Western blot assays (Fig. 5A–B) showed that Sirt1 expression was significantly decreased, but ac-Foxo1 expression was obviously increased in the MI/R group compared with the Sham group. Notably, these effects induced by MI/R were obviously reversed by OPA treatment; that is, Sirt1 expression significantly increased after OPA treatment, and ac-Foxo1 expression significantly decreased after OPA treatment. The detection of apoptosis-related proteins showed that compared with the mice subjected to MI/R alone, the mice subjected to MI/R and treated with OPA exhibited obviously decreased expression of Bax and cleaved caspase-3 and increased expression of Bcl-2, indicating that OPA could reduce the MI/R-induced apoptosis of cardiomyocytes.

Therefore, OPA could activate the Sirt1/Foxo1 signaling pathway and inhibit the apoptosis of cardiomyocytes in MI/R mice.

Effects of OPA on the viability and apoptosis of H/R–treated H9c2 cells

An H/R injury model was established in H9c2 cells to confirm the effects of OPA on MI/R injury and the underlying mechanism in vitro. A CCK-8 assay was performed to evaluate cardiomyocyte viability in the different groups. As shown in Fig. 6A, OPA treatment had no significant effect on the viability of cardiomyocytes in which H/R was not induced. In Fig. 6B, compared to that of the control cells, the cell viability of the H/R–induced H9c2 cells was decreased by approximately 45.61%. Treatment with OPA markedly increased the H/R–mediated decrease in cell viability in a dose-dependent manner. Specifically, compared with that in the H/R group, cell viability in the H/R+OPA (0.1 μM) group, H/R+OPA (1 μM) group and H/R+OPA (10 μM) group were increased by approximately 5.05%, 10.41% and 14.53%, respectively. In addition, the flow cytometry results suggested that cell apoptosis in the H/R group was significantly higher than that in the Control group by 50.84%. Nevertheless, compared with that in the H/R group, the cell viability in the H/R+OPA (0.1 μM) group, H/R+OPA (1 μM) group and H/R+OPA (10 μM) group were decreased by approximately 23.26%, 29.05% and 40.50%, respectively (Fig. 6C). These results
indicated that OPA could increase the cardiomyocyte viability and inhibit the cardiomyocyte apoptosis induced by H/R in vitro.

OPA activates the Sirt1/Foxo1 signaling pathway and inhibits apoptosis of cardiomyocytes in H/R-treated H9c2 cells

The effects of OPA on the expression levels of Sirt1, ac-Foxo1, Bcl2, Bax and cleaved Caspase-3 in H/R-treated H9c2 cells were analyzed by western blot to elucidate the regulatory mechanism (Fig. 7A–B). Consistent with the in vivo results, the Sirt1 and Bcl-2 levels were notably reduced, but the ac-FoxO1, Bax and cleaved Caspase-3 levels were significantly increased in the H/R group compared with the Control group. However, when compared with those in the Control group, the Sirt1 and Bcl-2 levels were notably increased but the ac-FoxO1 and cleaved Caspase-3 levels were significantly decreased in the H/R+OPA (0.1 μM) group, H/R+OPA (1 μM) group and H/R+OPA (10 μM) group, indicating that OPA could promote the Sirt1/Foxo1 pathway and inhibit apoptosis of cardiomyocytes in an in vitro MI/R injury model.

DISCUSSION

With the development of the social economy and changes in people’s lifestyles, the risk factors for cardiovascular disease continue to increase. Tissue injury caused by myocardial ischemia is an important cause of fatal diseases and is commonly observed in clinical practice. Many mechanisms, including reactive oxygen species (ROS) production, inflammation, apoptosis, mitochondrial dysfunction, intracellular calcium overload, etc., are involved in the pathophysiological processes of myocardial ischemia/reperfusion injury (Song et al., 2017; Mastrocola et al., 2016; Jin et al., 2018). Understanding the complexity of pathological reperfusion injury and its mechanisms may lead to the development of a promising therapeutic strategy for cardiac I/R injury. In our current study, we found that OPA protected mouse hearts (in vivo) and H9c2 cells (in vitro) against I/R injury by regulating the Sirt1/Foxo1-mediated apoptosis pathway.

The mouse model of MI/R was established by ligating the anterior descending branch of the left coronary artery, and the cardiac function, and hemodynamic and histopathological changes were evaluated. The EF and FS are important indicators of cardiac function (Bai et al., 2017). In this study, treatment with OPA significantly improved the EF and FS of the MI/R mice. Necrosis is also one of the most common forms of cell death in the cardiac tissue after I/R injury. Damage to the myocardial cell membrane leads to the release of myocardial enzymes and proteins, including CK-MB, cTnI and cTnT, into the peripheral blood, and these enzymes and proteins are widely used as biomarkers of myocardial injury in clinical practice (Guo et al., 2019). Therefore, the levels of CK-MB, cTnI and cTnT in peripheral blood can reflect the degree of myocardial ischemia-induced necrosis. Here, OPA treatment reduced the MI/R-induced increase in the levels of CK-MB, cTnI and cTnT, indicating that OPA mitigated MI/R injury. Furthermore, the clear pathological changes in the myocardial tissue observed by H&E staining also reflected the protective effect of OPA against MI/R injury.

Sirt1 is a member of the Sir2uin family. Sirtuins are class III histone deacetylase transferases that rely on nicotinamide adenine dinucleotide (NAD+) for deacetylation (Sundaresan et al., 2011). Sirt1 can regulate many transcription factors by deacetylation to extensively regulate various processes, such as cell survival, apoptosis, growth, metabolism and aging (Higashida et al., 2013). Mounting evidence has proven that Sirt1 is involved in MI/R injury (Ding et al., 2015; Potenza et al., 2019). In particular, Sirt1 regulates the downstream protein Foxo1 by deacetylation, which inhibits apoptotic pathways and protects against the MI/R-induced injury (Yang et al., 2013; Yamamoto et al., 2011; Yu et al., 2016). Consistent with previous research, the present study found that Sirt1 expression was significantly downregulated in the MI/R group, which was accompanied by enhanced Ac-Foxo1 expression and increased cardiac apoptosis. Both, the in vivo and in vitro studies showed that OPA treatment promoted an obvious increase in Sirt1 expression and Foxo1 deacetylation. The activated Sirt1 pathway was also related to the increased expression of anti-apoptotic proteins (Bcl-2) and decreased expression of pro-apoptotic proteins (Bax and cleaved Caspase-3). Together, these data demonstrate that the myocardial protection achieved by OPA treatment is mediated by activating Sirt1 signaling, and OPA-induced Sirt1 activation can inhibit Foxo1 acetylation, thus promoting anti-apoptotic effects.

Based on the abundant evidence showing the protective effect of paeoniflorin (a structural analog of OPA) against MI/R injury (Chen et al., 2018; Han et al., 2016a; Wu et al., 2019), and the reported inhibitory effects of OPA on oxidative damage and inflammation in mesangial cells and LPS-stimulated RAW264.7 cells (Yoo et al., 2018a), we speculate that OPA may protect against the MI/R injury. Our experiments successfully verified the above hypothesis and elucidated the mechanism of action by which OPA protects against MI/R injury, namely, by regulating the Sirt1/Foxo1-mediated apoptosis signals. However, whether this mechanism affects apoptosis that is caused by oxidative damage, mitochondrial dysfunction or inflammation remains to be further studied.

CONCLUSION

Overall, our findings revealed for the first time that OPA plays a protective role in MI/R injury. More importantly, the Sirt1/Foxo1-mediated apoptotic pathway was found to play a critical role in regulating the cardioprotective effects of OPA. These results emphasize that OPA may serve as a novel agent for the treatment of MI/R injury in clinical cardiac surgery and ischemic heart diseases.

Acknowledgments

Not applicable.

Funding

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available.

Ethics approval and consent to participate

All the procedures were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH publication NO. 85-23, revised in 1996). The protocol was reviewed and approved by the Ethical Com-
mitte of Zhejiang Medical Chinese University before the animal study (No. ZSL1-2017-059).

REFERENCES

Bai R, Yin X, Feng X, Cao Y, Wu Y, Zhu Z, Li C, Tu P, Chai X (2017) Cordyceps hbensis Hemsl. protects against myocardial injury by attenuating inflammation and fibrosis via NF-κB and JAK2-STAT3 signaling pathways. J Ethnopharmacol 207: 174–183. https://doi.org/10.1016/j.jep.2017.06.020

Buja L. M, J, T. H, J. I. (2013) The pathobiology of acute coronary syndromes: clinical implications and central role of the mitochondria. Tex Heart Inst J 40: 223–228.

Chen D, Dou J (2015) Paoninol ameliorates acute myocardial infarction of rats by inhibiting inflammation and inducible nitric oxide synthase signaling pathways. Mol Med Rep 12: 3937–3943. https://doi.org/10.3892/mmr.2015.3870

Chen H, Dong Y, He X, Li J, Wang J (2018) Paoninol improves cardiac function and decreases adverse postinfarction left ventricular remodeling in a rat model of acute myocardial infarction. Drug Design Development Therapy 12: 823–836. https://doi.org/10.2147/DDDT.S163460

Chen Y-F, Wu K-J, W Wood G (2013) Paeoninol ameliorates myocardial ischemia/reperfusion injury by activating Notch1 diomyocytes from ischemia/reperfusion injury by activating Notch1. J Mol Cell Cardiol 1569-1575.

Feng C, Liu M, Shi X, Yang W, Kong D, Duan K, Wang Q (2010) Pharmacokinetic properties of paeoninol albolrhm and oxypane- coflorin and oral garlic of extracts of Radix Paeoniae Raima and Radix Paronias Alba in rats. J Ethnopharmacol 130: 407–413. https://doi.org/10.1016/j.jep.2010.05.028

Findexgold IA, Asurma P, Francis DP (2013) Mortality from ischemic heart disease by country region and age: Statistics from World Health Organisation and United Nations. Int J Cardiol 168: 934–945. https://doi.org/10.1016/j.ijcard.2012.10.046

Gao C, Zhang J, Zhang P, X, Zhang Z, Zhao L, Li F, Zhao G (2019) Ginkgoide B ameliorates myocardial ischemia-reperfusion injury in rats via inhibiting endoplasmic reticulum stress. Drug Design Development Therapy 13: 767. https://doi.org/10.2147/DDDT.S127010

Huang X-H, Li X-H, Hong X, Zhao N, Xiao Y-F, Wang L-F, Tang F, Jiang K, Sun Y-S, Deng Y-C (2016) CD36 deficiency protects the heart from ischemia/reperfusion injury through activating SIRT1/FOXO signalling pathway. Oxid Med Cell Longevity 2016: 7410257. https://doi.org/10.1155/2016/7410257

Higashida K, Kim SH, Jung SR, Asaka M, Holloszy JO, Han D-H (2010) DUSP1 alleviates cardiac ischemia/reperfusion injury by suppressing the Mff-required mitochondrial fission and Bnip3-mediated preconditioning on myocardial ischemia-reperfusion (I/R) injury in rats. Plos One 14: e0210654. https://doi.org/10.1371/journal.pone.0210654

Qian G-Q, Ding J, Zhang X, Yin X, Gao Y, Zhao G-P (2015) Preconditioning with glycyrhizin from glycyrrhiza f.linn. promotes rat hearts from ischemia/reperfusion injury via endothelial nitric oxide pathway. Pharmazie 71: 292–296. https://doi.org/10.1016/j.ymj.2015.03.081

Shi Y, Valverde CA, Sánchez G, Said M, Rodriguez JS, Portiansky EK, Kalcelcz MA, Dedman JR, Donoso P, Kranias EG (2010) The signaling of CaMKII-mediated apoptosis and necrosis in the ischemia/reperfusion injury. J Mol Cell Cardiol 48: 1298–1306. https://doi.org/10.1016/j.ygccl.2010.02.001

Song H, Yan C, Tian X, Zhu N, Li Y, Liu D, Liu Y, Liu M, Peng C, Zhang Q (2017) CREG protects from myocardial ischemia/reperfusion injury by regulating myocardial autophagy and apoptosis. Basic Clin Pharmacol Toxicol 1183: 1893-1903. https://doi.org/10.1111/jbbs.2016.11.015

Sundaresan NR, Pillai VB, Gupta MP (2011) Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J Mol Cell Cardiol 51: 614–618. https://doi.org/10.1016/j.jmcc.2011.01.008

Wang J-X, Zhang XJ, Li Q, Wang K, Wang Y, Jiao JQ, Feng C, Teng S, Zhou LY, Gong YJ (2015) MicroRNA-103/107 regulate programmed necrosis and myocardial ischemia/reperfusion injury through targeting FADD. Cire Res 117: 352–365. https://doi.org/10.1161/CIRCRESAHA.117.307851

Wang K, Li P, Liu C, An T, Zhang J, Zhou L, Wang M, Dong Y, Li G, Gao JI (2016) The long noncoding RNA NRF regulates programmed necrosis and myocardial injury during ischemia and reperfusion by targeting miR-873. Cell Death Differ 23: 1394. https://doi.org/10.1038/cdd.2016.200

Wang X, Yuan B, Cheng B, Liu Y, Zhang B, Wang X, Lin Y, Yang B, Gong GJ (2019) Crocin alleviates myocardial ischemia/reperfusion-induced endoplasmic reticulum stress via regulation of miR-34a-5p/NF-κB signaling pathway. Yonsei Med J 51: 123–130. https://doi.org/10.3349/ejym.2019.51.1.123

Wu F, Ye B, Wu X, Lin X, Li Y, Wu Y, Tong I. (2012) Paeoninol on rat myocardial ischemia reperfusion injury of protection and mechanism research. Pharmacology 105: 281–288. https://doi.org/10.1155/2012/453853

Wang Z, Zheng L (2016a) Paeoninol protects diabetic mice against myocardial ischemic injury by attenuating inflammation and fibrosis pathways. Oxidative Med Cell Longevity 2016: 7410257. https://doi.org/10.1155/2016/7410257

Yu L, Sun Y, Cheng L, Jin Z, Yang Y, Zhai M, Pei H, Wang X, Zhang B, Wang K, Wang Y, Jiao JQ, Feng C, Liu M, Shi X, Yang W, Kong D, Duan K, Wang Q (2018) Paoninol improves myocardial ischemia by activating Nrf2 signaling pathway in vitro. Medine 10: 2866–2873. https://doi.org/10.1007/srep23693

Mastrocola R, Penna C, Tullio F, Femminì S, Nigro D, Chiavza F, Sorge L, Collotta D, Allauri G, Cocco M (2016) Pharmacological inhibition of NLRP3 inflammasome attenuates myocardial ischemia/reperfusion injury by activation of RISK and mitochondrial pathways. Oxidative Med Cell Longevity 2016: S271251. https://doi.org/10.1155/2016/S271251

Nizamudinova IT, Jin YG, Kim JS, Yean MH, Kang SS, Kim YS, Lee JH, Seo HG, Kim HJ, Chang KC (2008) Paoninol and paoniflorin the main active principles of Paeonia albiflora protect the heart from myocardial ischemia/reperfusion injury in rats. Planta Med 74: 14–18. https://doi.org/10.2174/0032094077735777

Potenza MA, Sgarrà I, Nacci C, Leo V, De Salvia MA, Montagnani M (2019) Activation of AMPK/SIRT1 axis is required for adeno-